DVAX: יחס שווי שוק להכנסות Dynavax Technologies

Dynavax Technologies (DVAX) enjoys high physician confidence following the success of its hepatitis B vaccine. The price-to-sales ratio reflects the current market valuation, with the metric standing at 5.50. The business is protected by the mandatory nature of immunization, which ensures stability. However, reliance on a single flagship product and sector pressure create certain risks for growth.

When selecting defensive assets, investors seek a combination of stable cash flow and fair market value. For Dynavax Technologies (DVAX), scaling Heplisav-B vaccine sales creates operating leverage, making the market cap-to-revenue ratio a key indicator for assessing technology monetization efficiency and the extent of the premium paid for future earnings growth relative to current operating sales.